PDF herunterladen
CC BY-NC-ND 4.0 · Planta Medica International Open 2020; 07(04): e145-e149
DOI: 10.1055/a-1302-4570
Original Papers

Saikosaponin D Ameliorates Mechanical Hypersensitivity in Animal Models of Neuropathic Pain

Gyeongbeen Lee
1   Biocenter, Gyeonggido Business and Science Accelerator, Suwon, Korea
,
Yeon-Ju Nam
1   Biocenter, Gyeonggido Business and Science Accelerator, Suwon, Korea
,
Woo Jung Kim
1   Biocenter, Gyeonggido Business and Science Accelerator, Suwon, Korea
,
Bo Hye Shin
2   Peripheral Neuropathy Research Center, Dong-A University College of Medicine, Busan, Korea
,
Jong Suk Lee
1   Biocenter, Gyeonggido Business and Science Accelerator, Suwon, Korea
,
Hwan Tae Park
2   Peripheral Neuropathy Research Center, Dong-A University College of Medicine, Busan, Korea
3   Department of Molecular Neuroscience, Dong-A University College of Medicine, Busan, Korea
,
Pansoo Kim
1   Biocenter, Gyeonggido Business and Science Accelerator, Suwon, Korea
,
Ji Hyun Lee
4   Division of Hemato-oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea
,
Yongmun Choi
1   Biocenter, Gyeonggido Business and Science Accelerator, Suwon, Korea
› Institutsangaben Funding: This work was supported by the Support Program for Creative Industry Institutes (R0003950, MOTIE, Korea) and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MIST) (NRF-2016R1A5A2007009 and NRF-2017R1C1B5014 853). We would also like to acknowledge the generous financial support from the Gyeonggi provincial government.
› Weitere Informationen
   Lizenzen und Reprints

Abstract

We have previously identified saikosaponins as transient receptor potential ankyrin 1 antagonists and showed that saikosaponin D improves neuropathic pain induced by the anticancer drug vincristine in mice. In order to gain more insight into the therapeutic effects of saikosaponin D, we tested saikosaponin D in animal models of neuropathic pain induced by either streptozotocin, which mimics diabetes, or paclitaxel, a commonly used chemotherapy treatment. Our findings indicate that although saikosaponin D improved pain outcomes in neuropathic pain models, the mechanisms underlying the therapeutic effects of saikosaponin D appear to differ between streptozotocin- and paclitaxel-induced pain. Streptozotocin-induced neuropathic pain was significantly alleviated 30 minutes after oral administration of saikosaponin D, while 1-day oral administration of saikosaponin D had little effect on paclitaxel-induced mechanical hypersensitivity. Attenuation of paclitaxel-induced mechanical hypersensitivity was evident only after repeated administration of saikosaponin D. Although the mechanisms underlying the therapeutic effects of saikosaponin D remain to be elucidated, our results shed new light on the therapeutic potential of saikosaponin D in the management of neuropathic pain caused by diabetes or chemotherapy.

Key words

Saikosaponin D neuropathic pain diabetes chemotherapy


Publikationsverlauf

Eingereicht: 09. Juni 2020
Eingereicht: 21. Oktober 2020

Angenommen: 29. Oktober 2020

Artikel online veröffentlicht:
07. Dezember 2020

© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, Freeman R, Truini A, Attal N, Finnerup NB, Eccleston C, Kalso E, Bennett DL, Dworkin RH, Raja SN. Neuropathic pain. Nat Rev Dis Primers 2017; 3: 17002
    CrossrefPubMedGoogle Scholar
  • 2 Fallon MT. Neuropathic pain in cancer. Br J Anaesth 2013; 111: 105-111
    CrossrefPubMedGoogle Scholar
  • 3 Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell 2009; 139: 267-284
    CrossrefPubMedGoogle Scholar
  • 4 St John Smith E. Advances in understanding nociception and neuropathic pain. J Neurol 2018; 265: 231-238
    CrossrefPubMedGoogle Scholar
  • 5 Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron 2006; 52: 77-92
    CrossrefPubMedGoogle Scholar
  • 6 Nativi C, Gualdani R, Dragoni E, Di Cesare Mannelli L, Sostegni S, Norcini M, Gabrielli G, la Marca G, Richichi B, Francesconi O, Moncelli MR, Ghelardini C, Roelens S. A TRPA1 antagonist reverts oxaliplatin-induced neuropathic pain. Sci Rep 2013; 3: 2005
    CrossrefPubMedGoogle Scholar
  • 7 Wang S, Kobayashi K, Kogure Y, Yamanaka H, Yamamoto S, Yagi H, Noguchi K, Dai Y. Negative regulation of TRPA1 by AMPK in primary sensory neurons as a potential mechanism of painful diabetic neuropathy. Diabetes 2018; 67: 98-109
    CrossrefPubMedGoogle Scholar
  • 8 Lehto SG, Weyer AD, Youngblood BD, Zhang M, Yin R, Wang W, Teffera Y, Cooke M, Stucky CL, Schenkel L, Geuns-Meyer S, Moyer BD, Wild KD, Gavva NR. Selective antagonism of TRPA1 produces limited efficacy in models of inflammatory- and neuropathic-induced mechanical hypersensitivity in rats. Mol Pain 2016; 12: 1744806916677761
    CrossrefPubMedGoogle Scholar
  • 9 Lee G, Choi J, Nam YJ, Song MJ, Kim JK, Kim WJ, Kim P, Lee JS, Kim S, No KT, Lee JH, Lee JK, Choi Y. Identification and characterization of saikosaponins as antagonists of transient receptor potential A1 channel. Phyto Res 2020; 34: 788-795
    CrossrefPubMedGoogle Scholar
  • 10 Ashour ML, Wink M. Genus Bupleurum: a review of its phytochemistry, pharmacology and modes of action. J Pharm Pharmacol 2011; 63: 305-321
    CrossrefPubMedGoogle Scholar
  • 11 Yuan B, Yang R, Ma Y, Zhou S, Zhang X, Liu Y. A systematic review of the active saikosaponins and extracts isolated from Radix Bupleuri and their applications. Pharm Biol 2017; 55: 620-635
    CrossrefPubMedGoogle Scholar
  • 12 Zhou X, Cheng H, Xu D, Yin Q, Cheng L, Wang L, Song S, Zhang M. Attenuation of neuropathic pain by saikosaponin a in a rat model of chronic constriction injury. Neurochem Res 2014; 39: 2136-2142
    CrossrefPubMedGoogle Scholar
  • 13 Barriere DA, Rieusset J, Chanteranne D, Busserolles J, Chauvin MA, Chapuis L, Salles J, Dubray C, Morio B. Paclitaxel therapy potentiates cold hyperalgesia in streptozotocin-induced diabetic rats through enhanced mitochondrial reactive oxygen species production and TRPA1 sensitization. Pain 2012; 153: 553-561
    CrossrefPubMedGoogle Scholar
  • 14 Hiyama H, Yano Y, So K, Imai S, Nagayasu K, Shirakawa H, Nakagawa T, Kaneko S. TRPA1 sensitization during diabetic vascular impairment contributes to cold hypersensitivity in a mouse model of painful diabetic peripheral neuropathy. Mol Pain 2018; 14: 1744806918789812
    CrossrefPubMedGoogle Scholar
  • 15 Starobova H, Vetter I. Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. Front Mol Neurosci 2017; 10: 174
    CrossrefPubMedGoogle Scholar
  • 16 Old EA, Nadkarni S, Grist J, Gentry C, Bevan S, Kim KW, Mogg AJ, Perretti M, Malcangio M. Monocytes expressing CX3CR1 orchestrate the development of vincristine-induced pain. J Clin Invest 2014; 124: 2023-2036
    CrossrefPubMedGoogle Scholar
  • 17 Trevisan G, Materazzi S, Fusi C, Altomare A, Aldini G, Lodovici M, Patacchini R, Geppetti P, Nassini R. Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade. Cancer Res 2013; 73: 3120-3131
    CrossrefPubMedGoogle Scholar
  • 18 Shim HS, Bae C, Wang J, Lee KH, Hankerd KM, Kim HK, Chung JM, La JH. Peripheral and central oxidative stress in chemotherapy-induced neuropathic pain. Mol Pain 2019; 15: 1744806919840098
    PubMedGoogle Scholar
  • 19 Bonin RP, Bories C, De Koninck Y. A simplified up-down method (SUDO) for measuring mechanical nociception in rodents using von Frey filaments. Mol Pain 2014; 10: 26
    CrossrefPubMedGoogle Scholar